Skip to main content
SpringerLink
Log in
Book cover

Precision Molecular Pathology of Prostate Cancer pp 13–26Cite as

Epidemiology and Etiology

  • Chapter
  • First Online:

  • 1224 Accesses

Part of the book series: Molecular Pathology Library ((MPLB))

Abstract

Prostate cancer is a very common but very heterogeneous disease. Biological aggressiveness exists across a wide spectrum, and how diseases at one end of the spectrum are related to those at the other is difficult to understand. To further understand the disease, researchers have long attempted to identify etiological drivers. Although risk factors have been identified, the pathway to disease development is not known. This chapter focuses on what we do know and highlights the incredibly large window of opportunity that genomics offers an avenue by which we may better understand prostate cancer and more fully define the etiology of the disease.

This is a preview of subscription content, log in via an institution.

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    Article  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  PubMed  Google Scholar 

  4. Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst. 1990;82(20):1624–8.

    Article  CAS  PubMed  Google Scholar 

  5. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548–52.

    Article  CAS  PubMed  Google Scholar 

  6. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.

    Article  PubMed  Google Scholar 

  7. Hoeksema MJ, Law C. Cancer mortality rates fall: a turning point for the nation. J Natl Cancer Inst. 1996;88(23):1706–7.

    Article  CAS  PubMed  Google Scholar 

  8. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708–17.

    Article  CAS  PubMed  Google Scholar 

  11. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  CAS  PubMed  Google Scholar 

  12. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.

    Article  CAS  PubMed  Google Scholar 

  14. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 1954;8(1):1–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Armitage P, Doll R. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer. 1957;11(2):161–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sweeney C. Prostate cancer therapy: going forwards by going backwards. Lancet Oncol. 2013;14(2):104–5.

    Article  PubMed  Google Scholar 

  17. Sweeney CJ, Chamberlain D. Insights into E3805: the CHAARTED trial. Future Oncol. 2015;11(6):897–9.

    Article  CAS  PubMed  Google Scholar 

  18. Statistics OfN. Cancer incidence and mortality in the United Kingdom, 2008-10. Office for National Statistics Statistical Bulletin 2012.

    Google Scholar 

  19. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102(30):10604–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Epstein JI, Carmichael MJ, Partin AW, Walsh PC. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol. 1994;151(6):1587–92.

    Article  CAS  PubMed  Google Scholar 

  22. Damaschke NA, Yang B, Bhusari S, Svaren JP, Jarrard DF. Epigenetic susceptibility factors for prostate cancer with aging. Prostate. 2013;73(16):1721–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Woolf CM. An investigation of the familial aspects of carcinoma of the prostate. Cancer. 1960;13:739–44.

    Article  CAS  PubMed  Google Scholar 

  24. Bratt O, Damber JE, Emanuelsson M, Gronberg H. Hereditary prostate cancer: clinical characteristics and survival. J Urol. 2002;167(6):2423–6.

    Article  CAS  PubMed  Google Scholar 

  25. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992;89(8):3367–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ishak MB, Giri VN. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1599–610.

    Article  PubMed  Google Scholar 

  27. Stadler ZK, Vijai J, Thom P, Kirchhoff T, Hansen NAL, Kauff ND, et al. Genome-wide association studies of cancer predisposition. Hematol Oncol Clin North Am. 2010;24(5):973–96.

    Article  PubMed  Google Scholar 

  28. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A. 2006;103(38):14068–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ, International Consortium for Prostate Cancer G. Where are the prostate cancer genes?—a summary of eight genome wide searches. Prostate. 2003;57(4):261–9.

    Article  CAS  PubMed  Google Scholar 

  31. Ostrander EA, Kwon EM, Stanford JL. Genetic susceptibility to aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1761–4.

    Article  CAS  PubMed  Google Scholar 

  32. Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105(8):1230–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106(10):1697–701.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Fedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM. Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2437–44.

    Article  PubMed  Google Scholar 

  35. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–314.

    Article  PubMed  Google Scholar 

  36. Talcott JA, Spain P, Clark JA, Carpenter WR, Do YK, Hamilton RJ, et al. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer. 2007;109(8):1599–606.

    Article  PubMed  Google Scholar 

  37. Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer EM. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J Urol. 2014;191(1):60–7.

    Article  PubMed  Google Scholar 

  38. Fedewa SA, Jemal A. Prostate cancer disease severity and country of origin among black men in the United States. Prostate Cancer Prostatic Dis. 2013;16(2):176–80.

    Article  CAS  PubMed  Google Scholar 

  39. Coard KC, Skeete DH. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica. BJU Int. 2009;103(11):1482–6.

    Article  PubMed  Google Scholar 

  40. Kampel LJ, Tse K, Joseph M. Clinicopathologic findings in Jamaican men with prostate cancer. ASCO Meeting Abstracts. 2011;29(7_suppl):214.

    Google Scholar 

  41. Yarney J, Vanderpuye V, Mensah J. Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men. Urol Oncol. 2013;31(3):325–30.

    Article  PubMed  Google Scholar 

  42. Kabore FA, Zango B, Sanou A, Yameogo C, Kirakoya B. Prostate cancer outcome in Burkina Faso. Infect Agent Cancer. 2011;6 Suppl 2:S6.

    Google Scholar 

  43. Obiorah CC, Nwosu SO. A histopathological study of carcinoma of the prostate in Port Harcourt, Nigeria. Niger J Clin Pract. 2011;14(3):363–7.

    Article  CAS  PubMed  Google Scholar 

  44. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.

    Article  CAS  PubMed  Google Scholar 

  45. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int. 2006;97(6):1190–3.

    Article  CAS  PubMed  Google Scholar 

  46. Trinh QD, Nguyen PL, Leow JJ, Dalela D, Chao GF, Mahal BA, et al. Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. J Natl Cancer Inst. 2015;107(6):djv054.

    Article  PubMed  Google Scholar 

  47. Lichtensztajn DY, Gomez SL, Sieh W, Chung BI, Cheng I, Brooks JD. Prostate cancer risk profiles of Asian-American men: disentangling the effects of immigration status and race/ethnicity. J Urol. 2014;191(4):952–6.

    Article  PubMed  Google Scholar 

  48. Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105(14):1050–8.

    Article  CAS  PubMed  Google Scholar 

  49. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122(5):327–34.

    Article  CAS  PubMed  Google Scholar 

  50. Wynder EL. Nutrition and cancer. Fed Proc. 1976;35(6):1309–15.

    CAS  PubMed  Google Scholar 

  51. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol. 1984;120(2):244–50.

    Article  CAS  PubMed  Google Scholar 

  52. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.

    Article  PubMed  Google Scholar 

  53. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.

    Article  PubMed  Google Scholar 

  55. Bhindi B, Kulkarni GS, Finelli A, Alibhai SM, Hamilton RJ, Toi A, et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol. 2014;66(5):841–8.

    Article  PubMed  Google Scholar 

  56. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001;91(3):421–30.

    Article  CAS  PubMed  Google Scholar 

  57. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17(8):989–1003.

    Article  PubMed  Google Scholar 

  58. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(1):63–9.

    Article  PubMed  Google Scholar 

  59. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1977–83.

    Article  PubMed  Google Scholar 

  60. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007;109(4):675–84.

    Article  PubMed  Google Scholar 

  61. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800–9.

    Article  CAS  PubMed  Google Scholar 

  62. Masko EM, Allott EH, Freedland SJ. The relationship between nutrition and prostate cancer: is more always better? Eur Urol. 2013;63(5):810–20.

    Article  CAS  PubMed  Google Scholar 

  63. Nilsen TI, Romundstad PR, Vatten LJ. Recreational physical activity and risk of prostate cancer: a prospective population-based study in Norway (the HUNT study). Int J Cancer. 2006;119(12):2943–7.

    Article  CAS  PubMed  Google Scholar 

  64. Johnsen NF, Tjonneland A, Thomsen BL, Christensen J, Loft S, Friedenreich C, et al. Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Int J Cancer. 2009;125(4):902–8.

    Article  CAS  PubMed  Google Scholar 

  65. Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev. 2005;14(1):275–9.

    PubMed  Google Scholar 

  66. McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J Natl Cancer Inst. 2014;106(4):dju036.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Mina DS, Connor MK, Alibhai SM, Toren P, Guglietti C, Matthew AG, et al. Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: a randomized study. Can Urol Assoc J. 2013;7(11-12):E692–8.

    Article  PubMed Central  Google Scholar 

  68. Punnen S, Hardin J, Cheng I, Klein EA, Witte JS. Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. PLoS One. 2011;6(11):e27711.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Major JM, Cross AJ, Watters JL, Hollenbeck AR, Graubard BI, Sinha R. Patterns of meat intake and risk of prostate cancer among African-Americans in a large prospective study. Cancer Causes Control. 2011;22(12):1691–8.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. Cancer Prev Res. 2011;4(12):2110–21.

    Article  CAS  Google Scholar 

  71. Alexander DD, Morimoto LM, Mink PJ, Cushing CA. A review and meta-analysis of red and processed meat consumption and breast cancer. Nutr Res Rev. 2010;23(2):349–65.

    Article  CAS  PubMed  Google Scholar 

  72. Montague JA, Butler LM, Wu AH, Genkinger JM, Koh WP, Wong AS, et al. Green and black tea intake in relation to prostate cancer risk among Singapore Chinese. Cancer Causes Control. 2012;23(10):1635–41.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Ozten-Kandas N, Bosland MC. Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants—in vivo evidence. J Carcinog. 2011;10:27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Newmark HL, Heaney RP. Dairy products and prostate cancer risk. Nutr Cancer. 2010;62(3):297–9.

    Article  CAS  PubMed  Google Scholar 

  75. Lampe JW. Dairy products and cancer. J Am Coll Nutr. 2011;30(5 Suppl 1):464S–70S.

    Article  CAS  PubMed  Google Scholar 

  76. Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Zeisel SH, Willett WC, et al. Choline intake and risk of lethal prostate cancer: incidence and survival. Am J Clin Nutr. 2012;96(4):855–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Sonn GA, Aronson W, Litwin MS. Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis. 2005;8(4):304–10.

    Article  CAS  PubMed  Google Scholar 

  78. Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, et al. Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr. 2012;96(1):111–22.

    Article  CAS  PubMed  Google Scholar 

  79. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62(8):2220–6.

    CAS  PubMed  Google Scholar 

  80. Augustsson K, Skog K, Jagerstad M, Dickman PW, Steineck G. Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study. Lancet. 1999;353(9154):703–7.

    Article  CAS  PubMed  Google Scholar 

  81. Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC, et al. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer. 1999;33(1):20–5.

    Article  CAS  PubMed  Google Scholar 

  82. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989;49(7):1857–60.

    CAS  PubMed  Google Scholar 

  83. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859–64.

    Article  PubMed  Google Scholar 

  84. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39–51.

    Article  CAS  PubMed  Google Scholar 

  85. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014;66(6):1054–64.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010;100(4):693–701.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, et al. Smoking is a predictor of adverse pathological features at radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015;22(7):658–62.

    Article  PubMed  Google Scholar 

  89. Roberts WW, Platz EA, Walsh PC. Association of cigarette smoking with extraprostatic prostate cancer in young men. J Urol. 2003;169(2):512–6. discussion 6

    Article  PubMed  Google Scholar 

  90. Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, et al. Association of cigarette smoking and smoking cessation with biochemical recurrence of prostate cancer in patients treated with radical prostatectomy. Eur Urol. 2015;68(6):949–56.

    Article  PubMed  Google Scholar 

  91. Joshu CE, Mondul AM, Meinhold CL, Humphreys EB, Han M, Walsh PC, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst. 2011;103(10):835–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer. 2014;120(2):197–204.

    Article  CAS  PubMed  Google Scholar 

  93. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, et al. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer. 2006;106(1):79–86.

    Article  CAS  PubMed  Google Scholar 

  94. Lee J, Cooke JP. Nicotine and pathological angiogenesis. Life Sci. 2012;91(21-22):1058–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Birrane G, Li H, Yang S, Tachado SD, Seng S. Cigarette smoke induces nuclear translocation of heme oxygenase 1 (HO-1) in prostate cancer cells: nuclear HO-1 promotes vascular endothelial growth factor secretion. Int J Oncol. 2013;42(6):1919–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Yang S, Long M, Tachado SD, Seng S. Cigarette smoke modulates PC3 prostate cancer cell migration by altering adhesion molecules and the extracellular matrix. Mol Med Rep. 2015;12(5):6990–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34(3):J258–65.

    Article  CAS  PubMed  Google Scholar 

  98. Moreira D, Nickel JC, Gerber L, Muller R, Andriole G, Castro-Santamaria R, et al. Smoking is associated with acute prostatic inflammation in men with a negative prostate biopsy: results from the REDUCE study. J Urol. 2013;189(4):E480.

    Article  Google Scholar 

  99. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer. 2010;127(7):1680–91.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada

    Padraic O’Malley M.Sc., M.D., F.R.C.S.C.

Authors
  1. Padraic O’Malley M.Sc., M.D., F.R.C.S.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Padraic O’Malley M.Sc., M.D., F.R.C.S.C. .

Editor information

Editors and Affiliations

  1. Pathology and Laboratory Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA

    Brian D. Robinson

  2. Pathology and Laboratory Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA

    Juan Miguel Mosquera

  3. Institute for Academic Medicine, Houston Methodist Hospital Pathology and Genomic Medicine, Weill Medical College of Cornell University, Houston, Texas, USA

    Jae Y. Ro

  4. Institute for Academic Medicine, Houston Methodist Hospital Pathology and Genomic Medicine, Weill Medical College of Cornell University, Houston, Texas, USA

    Mukul Divatia

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

O’Malley, P. (2018). Epidemiology and Etiology. In: Robinson, B., Mosquera, J., Ro, J., Divatia, M. (eds) Precision Molecular Pathology of Prostate Cancer. Molecular Pathology Library. Springer, Cham. https://doi.org/10.1007/978-3-319-64096-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64096-9_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64094-5

  • Online ISBN: 978-3-319-64096-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation